Connect with us

business

Are Drug Prices Immune to Inflation?

Published

on


Want an inflation hedge? Try drugs. Even historically high rates of inflation won’t necessarily lead to steeper prices for illegal substances like cannabis, MDMA, cocaine, and heroin. Not only do prices remain stable over the years, but quality has stayed the same and even improved in some cases. Why are illegal drug markets seemingly immune to inflation? 

Inflation  

Inflation is quite the buzzword these days. Inflation measures how much more expensive a set of goods and services has become over a certain period, usually a year, by using the consumer price index. It’s probably one of the most familiar words in economics, as inflation has historically been responsible for initiating long periods of instability in numerous countries across the globe. And we’re seeing a great deal of it in the United States lately.  

While inflation hasn’t been as dramatic these last couple years as it was immediately after the COVID-19 pandemic and shutdowns, the cost of goods is still rising. U.S. inflation rate for 2022 was 8.00%, a 3.3% increase from 2021. U.S. inflation rate for 2021 was 4.70%, a 3.46% increase from 2020. This year so far, the annual inflation rate for was 3.7% for the 12 months ended September, according to U.S. Labor Department data published on Oct. 12, 2023, but we will know the real stats after the end of the calendar year.  

Even though inflation is slowing down, the problem is that salaries never caught up. When we compare the average cost of a home in 2022, which was $349,000 and has gone up since then, with the average price from 2000 at $119,000; then factor in the minimum wage from those same years, $5.15 and $7.25 respectively, we can see some major discrepancies.  

Wages went up 40.8 percent over a 22-year period, meanwhile, the cost of housing has increased by 193.3 percent. And it’s not just the cost of housing, but everything is going up – groceries, gas, utilities, clothing, even little stuff like streaming and other memberships have doubled, even tripled, over the last couple of decades. The only product left that seems to have completely dodged inflation-related price spikes (beside Arizona Iced Tea), are illicit drugs.  

Street drug prices 

What’s interesting about street drugs, is that pricing is pretty standardized. They fall into a range, but overall, they have remained relatively stable over time. For example, when I was growing up, and eighth of flower was always $40-50. Sure we have more options now, even less than $10 in some markets, but overall, the price of a top-shelf eighth is still around $25-40.  

According to Teodora Groshkova, principal scientific analyst at the European Monitoring Centre for Drugs and Drug Addiction, it was believed to be due to a method known as “skimpflation”, where suppliers reduce the quality of whatever they are selling to offset rising production costs, but this does not seem to be the case here.  

“Any change in the [wider] market would typically be reflected in the drugs’ purity,” Groshkova says. “So far, however, the potency of cannabis products and the purity of other illicit drugs are increasing or at minimum staying the same.”   

How criminal organizations and other illegal drug producers have managed to skirt the pressures of inflation remains a mystery. While some might be going the “skimpflation” route to save some money, and others are horizontally integrating their businesses by controlling both import and distribution, that’s likely not the case for everyone. Groshkova suggests another possibility, which is quite simple, that drug dealers make so much money they’re able to better mitigate inflationary issues. “They’d rather not, but they can”, she adds.  

Pharmaceutical drug prices 

Many common prescription drugs are going up in price

Perhaps even more interesting than the stability of street drug prices, is the fact that while illegal substances have actually gone down in price overall, legal pharmaceutical drugs have been increasing. And even though this has been happening since the 1990s, it seems the problem has compounded in recent years. Per a Medicare study published in February 2022, prices increased faster than rates of inflation for more than half of all the drugs they cover between 2020 and 2022.  

A total of 3,911 drugs saw prices increases that were greater than inflation rates during that time period. Additionally, out of their 25 top selling medications, 23 percent were subject to price hikes. So nearly every single one of their most popular drugs, that they already make a lot of money on, were subject to price hikes.  

It’s so bad, that President Biden signed The Inflation Reduction Act of 2022 into law on August 16th of that year. Among other things, the bill includes several provisions to lower prescription medication costs for people with Medicare and reduce overall drug spending by the federal government. The legislation has strong bi partisan support, as well as support from the general public who are struggling to deal with rising and already high drug prices.  

Artificial inflation and price gouging  

Let’s break it all down real quick. The prices of legal products are going up while quality is dropping. Meanwhile, manufacturers of illegal products are raising the quality and keeping consumer prices the same, even less, for many drugs. To me, this indicates that much of the rapid inflation we’re seeing in other industries is artificial, driven by shady politicians, or, the companies themselves.  

Inflation can be an elusive foe: quietly making off with our savings and chunks of our paychecks and stealing away everything from vacations to favorite foods. Everyone agrees inflation is happening. What they don’t agree on is whodunit. The main suspects differ across party lines. Many economists and politicians on the right say inflation has been caused by government spending and various aid programs (stimulus checks, student debt forgiveness, Biden in the White House with the public purse). 

Many economists and politicians on the left point to the war in Ukraine (for pushing up oil prices, which bleeds into most everything else), and also greedy companies, many of which, despite tales of supply chain snarls and rising costs, have been bringing in record profits. (Corporations, in aisle 4, with the price gun.) 

It’s worth noting that corporate profits reached an all-time high this year with many companies seeing record profits. This, naturally, raises some eyebrows. If companies are struggling with costs and supply chains so much, where are all of these billions in profits coming from? It begins to seem like all of this corporate crying about rising costs might be a case of crocodile tears, as companies jack up prices for all of us. 

Rakeen Mabud is chief economist for the progressive think tank Groundwork Collaborative. “Companies are taking a spoonful of sugar off the … backs of families who are all really struggling to get by,” she said. Mabud has sat in on dozens of corporate earnings calls and says she often hears CEOs bragging about how much they were able to raise prices.  

Final thoughts  

For the time being at least, consumers are unlikely to notice any dramatic changes to the cost of getting high. drug prices inflation

Welcome cannabis aficionados! Thanks for making your way to Cannadelics.com, an independent news site going deep into the worlds of cannabis, psychedelics, and well beyond. We’re big on updates, so come by regularly. And get yourself signed up to the Cannadelics Weekly Newsletter, for the best in related product offerings, as well.



Source link

Continue Reading

banking

“A big deal”: What the feds’ move to reclassify marijuana means for Colorado cannabis

Published

on

By



Cannabis advocates in Colorado cheered the Biden Administration’s reported move to reclassify marijuana and said the decision likely would reduce businesses’ tax burden significantly.

Industry leaders cautioned that such a move — if finalized — would not resolve some major challenges facing the industry, such as limited access to banking. But they pointed to the symbolic importance of preparations by the U.S. Drug Enforcement Administration to downgrade the substance’s drug classification.

A man pours cannabis into rolling papers as he prepares to roll a joint the Mile High 420 Festival in Civic Center Park in Denver, April 20, 2024. (Photo by Kevin Mohatt/Special to The Denver Post)

Read the rest of this story on DenverPost.com.



Source link

Continue Reading

business

Astronauts to Test Cannabis Growth in Outer Space

Published

on

By


NASA‘s recent collaboration with the International Space Research Consortium to launch a mission testing the cultivation of cannabis in the microgravity of space has stirred a whirlwind of interest and controversy across the globe. This initiative aims to unravel the mysteries of how low-gravity environments affect plant growth, with cannabis serving as the pioneering subject. According to Dr. Alfred Terra, the esteemed lead scientist spearheading the project, the conditions in space present an “unparalleled opportunity” to push the boundaries of our understanding of botany and its applications in medicine and agriculture beyond Earth’s confines.

This ambitious endeavor aims to shed light on the potential for utilizing space-based agriculture to support long-duration space missions and future colonization efforts on other planets. The choice of cannabis as a research subject is particularly intriguing due to its complex biochemical makeup and its increasing use in medicinal therapies on Earth. Insights gained from how cannabis adapts to space’s harsh environment could lead to breakthroughs in growing food and medicinal plants in extraterrestrial colonies.

Despite the scientific excitement surrounding the mission, the announcement has been met with its share of skepticism and criticism. Some members of the scientific community and the general public question the allocation of resources toward cannabis research in space, arguing that more pressing scientific and exploratory questions merit attention aboard the International Space Station (ISS). These critics call for a focus on projects that directly contribute to our understanding of space travel’s impacts on human physiology or further our knowledge of the cosmos.

However, the space agencies involved have been quick to highlight the broader implications of this research. They argue that studying cannabis growth in microgravity could offer invaluable insights into plant biology, stress responses, and the possibility of cultivating a variety of crops in space, which are crucial for the long-term sustainability of space exploration and eventual human settlement on other planetary bodies.

Amidst the debates over the mission’s merits and the speculation spurred by its announcement date—April 1st—lies a deeper curiosity about the future of space exploration and the role of innovative agricultural research in that journey. The timing has led some to question the announcement’s authenticity, pondering whether it could be an elaborate April Fool’s Day jest aimed at sparking discussion or simply a coincidence that has amplified the public’s fascination with the project.

Whether viewed as a bold step into the future of space agriculture or a controversial choice of research focus, the mission symbolizes a growing intersection between space exploration and the quest to understand and utilize biological processes in unprecedented environments. As the launch date approaches and preparations continue, the world watches, eager to see what insights this venture might unfold about cannabis, plant science, and the potential for life beyond Earth.

*** This article is an April Fool’s Day joke ***



Source link

Continue Reading

business

A Hiring Wave on the Horizon

Published

on

By


The U.S. cannabis industry is on the brink of a significant hiring wave in 2024, spurred by a 12% increase in legal sales in 2023, reaching $29 billion. This growth, alongside potential federal reclassification of cannabis, is expected to create up to 100,000 new jobs, particularly in the retail sector, where 93% of companies plan to expand their workforce. The Vangst 2024 Cannabis Salary Guide highlights an industry ready to bounce back from previous economic stagnation, with a strong emphasis on experience, adaptability, and cultural fit in prospective employees.

The cannabis sector is poised for a massive expansion in employment opportunities in 2024, following a year of economic challenges and layoffs. This optimistic forecast comes from Vangst’s latest industry salary guide, which anticipates a hiring boom driven by increased legal cannabis sales and the potential for federal rescheduling. The anticipated move to reclassify cannabis to Schedule III could significantly reduce tax burdens, increase company valuations, and attract more investors, according to Viridian Capital Advisors.

Retail cannabis companies are at the forefront of this hiring surge, with nearly all surveyed indicating plans to bolster their teams in response to growing demand and market expansion. The focus is not just on filling positions but on finding candidates who can navigate the evolving legal and market landscape, prioritize cultural fit, and possess strong communication skills over traditional qualifications.

Salaries in the cannabis industry have also seen an uptick, with top-end wages growing by 4.7%, outpacing the national non-cannabis average. However, the sector still trails behind others in offering comprehensive benefits packages, a gap that affects employee satisfaction and retention. The demand for health insurance and better work-life balance is clear among job seekers in the cannabis space.

Diversity and inclusion are gaining traction within cannabis company hiring practices, with a significant portion of companies implementing strategies to create a more inclusive workforce. The industry’s employment of veterans and individuals with disabilities highlights its diverse nature, but there remains room for improvement.

Why It Matters: This hiring wave marks a pivotal moment for the cannabis industry, signaling a shift towards recovery and growth after a period of stagnation. It underscores the industry’s resilience and its potential to contribute significantly to the economy through job creation and increased sales.

Potential Implications: The anticipated hiring boom in the cannabis industry could lead to wider acceptance and normalization of cannabis use, further influencing policy changes and societal attitudes. Additionally, the focus on diversity and inclusion could set a precedent for other sectors, promoting a more inclusive workforce across industries.

Source: Green Market Report



Source link

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media